Consensus guidelines establish updated measurable residual disease frameworks in acute myeloid leukemia, highlighting standardized risk categories and ultrahigh-sensitivity sequencing.
Key Points
To update and harmonize consensus recommendations for measurable residual disease assessment in acute myeloid leukemia across technical, clinical, and trial settings.
Conducted a two-stage Delphi consensus process among members of the European LeukemiaNet AML MRD Working Party.
Aligned recommendations with the 2022 European LeukemiaNet genetic risk classification and tailored guidance to distinct prognostic and genetic subgroups.
Formulated 56 total recommendations, with 53 achieving high consensus of at least 90%.
Introduced qualitative response categories defined as optimal, warning, or high risk of treatment failure to standardize measurable residual disease burden interpretation.
Recommended ultrahigh-sensitivity next-generation sequencing for FLT3 internal tandem duplication-mutated disease following intensive chemotherapy and prior to allogeneic hematopoietic cell transplantation.